UPPSALA, Sweden, June 29 /PRNewswire/ --

- Financing Led by SLS Invest Will Fund Gyros to Profitability

PLEASANTON, California, June 29 /PRNewswire/ --

- New LA-200E Tracks Up to 4,000 Wi-Fi Assets Including 802.11n

Trapeze Networks, a Belden brand (NYSE: BDC), today announced its new Trapeze LA-200E Location Appliance(TM), a system that quickly and continuously locates and tracks anything broadcasting a Wi-Fi signal. The Trapeze LA-200E doubles the number of clients it supports and is the first product supporting locating and tracking 802.11n clients. The LA-200E works in concert with Wi-Fi equipment from a wide variety of WLAN infrastructure providers in addition to Trapeze Networks NonStop Wireless infrastructure.

Location, Location, Location

PLEASANTON, California, June 29 /PRNewswire/ --

- Perimeter Security Solution: Ultimate Cyber Barrier

Today, Trapeze Networks, a Belden brand (NYSE: BDC), announced global availability of the Trapeze RF Firewall(TM), a location-based firewall securing wireless LAN networks (WLANs). The Trapeze RF Firewall is the first application available on the new Trapeze LA-200E Location Appliance, also announced today. (See June 29, 2009 press release, Demand for Location Services Driving Trapeze Networks to Deliver High Capacity Solutions.)

HSINCHU, Taiwan, R.O.C., June 29 /PRNewswire/ --

- Area reduction and performance gain with slim platform for analog and power management system-on-chip applications

PARIS, June 29 /PRNewswire/ --

- Provides Service Providers With a New Level of Control in the Management and Delivery of Targeted Mobile Advertisements

LONDON, June 29 /PRNewswire/ --

The European large scale micro metrology market is anticipated to register low growth during the first few quarters of 2009 due to the economic downturn. An upturn in the economic situation by the last quarter of 2009 is set to spur market growth with resurgent demand from the automotive industry. With an operational and capital expenditure freeze in all end-user segments, growth in this market is dependent on demand from the aerospace industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

GENEVA, June 29 /PRNewswire/ --

The Foundation for Research in Osteoporosis and Bone Disease (FROMO) announced the recipients of the 2009 Fellowship in Renal Physiology and Pathophysiology: Andreas Kistler, MD, PhD, Clinical Fellow at the Division of Nephrology of the University Hospital Zurich, Switzerland and Sara Damiano, PhD student in Nephrological Sciences at the Second University of Naples, Italy. The biotechnology company Amgen offered this educational grant to FROMO which is a Foundation based in Geneva to support research and teaching in the field of bone disease, in particular renal osteodystrophy which affects patients with severe renal insufficiency.

SAN RAMON, California, June 29 /PRNewswire/ --

- New energy harvesting, no battery required feature set expands ZigBee networks

The ZigBee(R) Alliance, a global ecosystem of companies creating wireless solutions for use in energy management, commercial and consumer applications, today announced development of the ZigBee Green Power feature set to establish a global, standard technology for self-powered devices operating through energy harvesting techniques. These devices will communicate seamlessly with existing ZigBee and ZigBee PRO networks and will enable maintenance free, environmentally friendly products that eliminate the need for wires and batteries to power control devices.

DUBAI, United Arab Emirates, June 29 /PRNewswire/ -- The market for water and wastewater treatment equipment in Gulf Cooperation Council (GCC) countries experienced rapid growth during 2008 driven by huge investments in infrastructure, real estate, petrochemicals, oil and gas and other sectors. However, the sub-prime mortgage crisis that hit western economies changed the business climate and there was a considerable decline in demand for most commodities. Crude oil prices plummeted to about $50 per barrel from a historic high of $145 per barrel, making investors wary of funding new projects.

SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.